What Zagros Pharmed Pars. Pharmacutical co. does

Zagros Pharmed Pars Pharmaceutical Co. (legal name: داروسازی زاگرس فارمد پارس, ticker: ددام) is an Iran-based, publicly listed pharmaceutical manufacturer operating for over four decades from its Borujerd, Lorestan Province production facility, with a corporate office in Tehran. The company manufactures both veterinary and human pharmaceutical products, with its veterinary division producing antibiotics (chlortetracycline, colistin, tiamulin, sulfa-based combinations), antiparasitics (benzimidazoles, salicylanilides), herbal formulations (Gastroherb, Bronchiherb), nutritional supplements, disinfectants, and growth promoters targeting livestock, poultry, aquaculture, bees, and companion animals. Its human pharmaceutical division produces injectable carbapenem antibiotics (meropenem, imipenem/cilastatin) for hospital use in treating serious infections. The company is recognized as Iran's largest veterinary drug manufacturer, holds GMP certification from Iran FDA, and is a subsidiary of the TIPO (Tolid Darou Pharmaceutical Investment Group) state-linked holding company.

The business model centers on B2B pharmaceutical sales through a multi-channel distribution network of specialized veterinary distributors (DD Vet, DPDCIR, Exir, Hejrat) and the Daroupakhsh distribution network (part of the same TIPO holding), supplemented by direct institutional and government procurement via public tenders. Products are sold via quote-based B2B pricing with no public consumer-facing pricing, and the company captures additional shareholder returns through public listing on the Tehran Stock Exchange, having declared a 745 IRR/share cash dividend for FY1404 (ending March 2025). End customers span livestock farmers, poultry operations, fish farms, beekeepers, veterinarians, and hospital pharmacies, with active export presence in the Middle East and Central Asia.

Recent operating performance shows exceptional momentum: monthly sales reached 108 billion IRR in Mordad 1404 (July/August 2025), up 204% year-over-year, with production volume up 77%. The company has launched a steady stream of new veterinary products (Oxfenazole in November 2023, Oxyzanid in February 2024) and continues to participate in major industry exhibitions including Iran Pharma and the International Livestock Exhibition. A leadership change in mid-2026 appointed Mojtaba Janzeni (PharmD, MBA) as Acting CEO, replacing prior CEO Dr. Rostayi, with strategic direction set by parent TIPO.

Name

Zagros Pharmed Pars. Pharmacutical co.

Legal name

Zagros Pharmed Pars Pharmaceutical Co. (داروسازی زاگرس فارمد پارس)

Website

https://zagrospharmed.com

Company type

Public

Founded year

1980

Operating status

Operating

Headcount range

11–50 employees

Short description

Zagros Pharmed Pars is an Iran-based, publicly listed pharmaceutical manufacturer producing veterinary antibiotics, antiparasitics, herbal formulations, and human injectable carbapenems, distributed across Iran through specialized veterinary distributors and the Daroupakhsh network to livestock farmers, poultry operations, hospitals, and exporters.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic & Private-Label Veterinary Pharmaceuticals (HLAMAEAM)

akta.pro secondary industries

Veterinary Pharmaceutical Wholesalers & Distributors (HLAMAIAA), Pet Pharmaceuticals & Veterinary Supply Distribution (CRAOAKAD)

Keywords

• Veterinary pharmaceuticals
• Animal health products
• Injectable antibiotics
• Livestock medicines
• Pharmaceutical manufacturing

Headquarters

HQ city

Tehran

HQ country

Iran

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Veterinary Pharmaceutical Sales: Sale of veterinary drugs and health products for livestock, poultry, aquaculture, and pets through distributor network and direct B2B channels.
2. Human Pharmaceutical Sales: Manufacturing and sale of human injectable antibiotics (carbapenems) for hospital and clinical use.
3. Stock Dividend: Listed on Tehran Stock Exchange (ticker: ددام). Distributed cash dividend of 745 Rials per share for fiscal year 1404 (ending March 2025).

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Zagros Pharmed Pars Pharmaceutical Co. manufactures and sells veterinary and human pharmaceutical products at its GMP-certified facility in Borujerd, Iran. Its veterinary line covers antibiotics, antiparasitics, vitamins, herbal remedies, growth promoters, disinfectants, and supplements for livestock, poultry, fish, bees, and pets. Its human pharmaceutical line consists of sterile injectable carbapenem antibiotics (Imipenem/Cilastatin and Meropenem) for hospital use. Products are distributed through specialized veterinary distributors and the Daroupakhsh parent-group distribution network across Iran and select export markets in the Middle East and Central Asia.

Product overview

Zagros Pharmed Pars Pharmaceutical Co. operates as a pharmaceutical manufacturer under the brand Damplran Razzak (داملران رازک), producing both veterinary and human medicines. The veterinary division offers antibiotics (including tetracyclines, colistin, tilmicosin, spectinomycin combinations, sulfonamides), antiparasitics (benzimidazoles, salicylanilides), herbal products (digestive and respiratory formulations), and nutritional supplements. The human pharmaceutical division produces injectable carbapenem antibiotics (Imipenem/Cilastatin and Meropenem). The company holds ISO certifications and GMP compliance, with over four decades of presence in Iran's veterinary pharmaceutical industry. Products are distributed through veterinary pharmacies and agricultural distribution networks across Iran.

Differentiator

Problem solved

Functional benefit

Products and services

• Gastroherb (گاسترو هرب) Herbal oral solution for poultry and turkeys that activates the digestive system, improves liver function, increases feed efficiency, and strengthens the immune system. Marketed for livestock and poultry producers seeking natural digestive stimulants.
• Bronchiherb (برونشی هرب) Herbal oral solution for poultry and turkeys that improves respiratory inflammation, disinfects airways, and facilitates mucus clearance. Marketed for livestock and poultry producers seeking natural respiratory treatments.
• Imipenem/Cilastatin (ایمی پنم/سیلاستاتین) Broad-spectrum carbapenem antibiotic for injection, available in 250/250mg, 500/500mg, and 750/750mg formulations for hospital and clinical use in treating intra-abdominal infections, bone and joint infections, skin infections, urinary tract infections, pneumonia, and septicemia.
• Meropenem (مروپنم) Broad-spectrum carbapenem antibiotic for IV injection, available in 500mg and 1000mg vials for hospital use in treating intra-abdominal infections, meningitis, respiratory tract infections, septicemia, skin infections, and urinary tract infections.
• Chlortetrin 20% (کلرتترین) Water-soluble veterinary antibiotic powder containing 200mg chlortetracycline hydrochloride per gram. Broad-spectrum tetracycline antibiotic for disease treatment in poultry, cattle, sheep, fish, and honeybees.
• Damacol (داماکول) Veterinary antibiotic containing Colistin sulfate, available in 20%, 1,200,000 IU, and 3,000,000 IU formulations. Used for prevention and treatment of intestinal infections caused by E. coli and Salmonella in poultry.
• Sulfadin (سولفادین) Veterinary oral solution containing Sulfaquinoxaline 25.6mg and Diaveridine 6.4mg per mL for treatment of coccidiosis and coccidial bloody diarrhea in poultry.
• Cosumix Plus (سولفاکلوپیریدازین + تری متوپریم) Veterinary antibiotic powder containing 100mg sulfachlorpyridazine sodium and 20mg trimethoprim per gram. Used for prevention and treatment of bacterial infections in poultry including air sac disease, CRD, and coliform septicemia.
• Tialorin 45% (تیالورین) Veterinary antibiotic containing Tiamulin hydrogen fumarate 45%. Used for control and treatment of mycoplasmosis (chronic respiratory disease, CRD) in poultry.
• Spectinolin (اسپکتینولین) Veterinary antibiotic sachet containing Lincomycin hydrochloride 33.3g and Spectinomycin sulfate 66.7g. Used for control and treatment of CRD complex in chicks, pullets, laying hens, and turkeys.
• Trisul (تریسول) Veterinary oral suspension containing Sulfadiazine sodium 400mg and Trimethoprim 80mg per mL. Used for prevention and treatment of colibacillosis, fowl cholera, salmonellosis, and infectious coryza in poultry.
• Oxyzanid 3.4% (اکسی زانید) Veterinary oral suspension containing 34mg Oxyclozanide per mL. Salicylanilide family antiparasitic for treatment and control of fascioliasis in cattle and sheep. Launched February 2024.
• Oxfenazole (اکسفنازول) Veterinary oral suspension containing Oxfendazole 22.5%. Benzimidazole family broad-spectrum antiparasitic for treatment of pulmonary and gastrointestinal nematodes and tapeworms in cattle, sheep, and goats. Launched November 2023.
• Heparenol (هپارنول) Veterinary hepatoprotective oral solution containing Sorbitol, Acetyl methionine, Lysine hydrochloride, Choline chloride, Betaine, and herbal extracts. Supports liver function, bile production, and digestion in animals.

Quantifiable outcome

• 204% year-over-year sales growth in Mordad 1404 (July/August 2025)
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core.

• Daroupakhsh Pharmaceutical Distribution NetworkcoreChannel Partner/ Reseller/ DistributorProducts distributed through the Daroupakhsh distribution network, Iran's oldest and largest pharmaceutical distribution company. Daroupakhsh provides the primary channel for reaching end customers across Iran.
• DD Vet Co (ddvetco.com)coreChannel Partner/ Reseller/ DistributorSpecialized veterinary pharmaceutical distribution company. Primary channel partner for veterinary product distribution.
• DPDCIR (dpdcir.com)coreChannel Partner/ Reseller/ DistributorVeterinary pharmaceutical distribution partner.
• Exir Pharmaceutical Distribution (exirpd.com)coreChannel Partner/ Reseller/ DistributorVeterinary pharmaceutical distribution partner.
• Hejrat Pharmaceutical Distribution (hejratco.com)coreChannel Partner/ Reseller/ DistributorVeterinary pharmaceutical distribution partner.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Vetoquinol: Independent global animal health company focused on veterinary pharmaceuticals, particularly for livestock and pets. Provides a relevant comparable for Zagros Pharmed's product mix (antibiotics, antiparasitics, specialty therapeutics) and its strategy of building share in livestock and aquaculture segments.

Broad incumbents

• Zoetis: Global leader in animal health and veterinary pharmaceuticals. While vastly larger and operating outside Iran, Zoetis represents the strategic archetype for what Zagros Pharmed is building toward — a diversified veterinary pharma franchise spanning livestock, poultry, aquaculture, and companion animals with proprietary products.
• Daroupakhsh Pharmaceutical Factories: Iran's oldest pharmaceutical distribution company and Zagros Pharmed's primary channel partner via TIPO. While distribution-focused, Daroupakhsh also operates manufacturing and offers a broader human + veterinary portfolio across Iran, making it a broader incumbent comparable in regulatory positioning.

Direct peers

• Exir Pharmaceutical: Iranian pharmaceutical manufacturer and one of Zagros Pharmed's named distribution partners. Both produce generic and veterinary pharmaceuticals for the Iranian market with overlapping antibiotic and supplement portfolios, making them the closest direct peer in scale, geography, and product mix.
• Tehran Nil Pharmaceutical: Iranian pharmaceutical manufacturer with a portfolio spanning human and veterinary medicines including antibiotics. Operates in Iran's GMP-regulated market with similar B2B distribution dynamics, comparable in size and customer segmentation to Zagros Pharmed.
• Pars Darou: Iranian pharmaceutical manufacturer operating under the same TIPO/TIPICO holding umbrella as Zagros Pharmed. Pars Darou produces human and veterinary medicines with comparable GMP-certified manufacturing and similar distribution channels, making it a closely comparable operating peer.
• Alborz Darou: Iranian pharmaceutical manufacturer producing antibiotics and other medicines for human and veterinary use. Similar size and regulatory environment as Zagros Pharmed, with overlapping product categories (antibiotics, injectables) and distribution channels across Iran.
• Jaber Ibn Hayyan Pharmaceutical: Iranian pharmaceutical manufacturer with both human and veterinary product lines, GMP-certified. Operates in Iran with comparable B2B distribution and government tender channels, making it a directly comparable Iranian peer in scale and customer mix.
• Kimiyadarou: Iranian veterinary and human pharmaceutical manufacturer with GMP certification. Produces antibiotics and related products for the same livestock, poultry, and aquaculture customers as Zagros Pharmed, making it a direct veterinary-pharma peer.
• Loghman Pharmaceutical: Iranian GMP-certified pharmaceutical manufacturer producing both human and veterinary medicines, including injectables. Operates in the same regulatory and distribution environment as Zagros Pharmed and competes for similar hospital and veterinary-pharmacy channels in Iran.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/zagrospharmed

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zagros Pharmed Pars. Pharmacutical co.